Palvella Therapeutics (PVLA) Depreciation & Amortization (CF) (2014 - 2024)
Palvella Therapeutics (PVLA) reported Depreciation & Amortization (CF) of -$30000.0 for Q1 2024, down 104.96% year-over-year from $605000.0 in Q2 2023, and up 84.85% on a QoQ basis from -$198000.0 in Q4 2023.
Palvella Therapeutics (PVLA) has 11 years of Depreciation & Amortization (CF) data on file, last reported at -$30000.0 in Q1 2024.
- Quarterly Depreciation & Amortization (CF) fell 104.96% year-over-year to -$30000.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was -$30000.0 (down 101.58% YoY) and the FY2023 annual result came in at $1.9 million, down 31.26% from the prior year.
- Depreciation & Amortization (CF) rose to -$30000.0 in Q1 2024 per PVLA's latest filing, from -$198000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $845000.0 in Q1 2022 and bottomed at -$198000.0 in Q4 2023.
- The 5-year median for Depreciation & Amortization (CF) is $609000.0 (2021), against an average of $553764.7.
- The widest annual swing landed in 2020, when Depreciation & Amortization (CF) jumped 1161.9%; it then plunged 134.43% in 2023.
- Tracing PVLA's Depreciation & Amortization (CF) over 5 years: stood at $688000.0 in 2020, then declined by 11.48% to $609000.0 in 2021, then slipped by 5.58% to $575000.0 in 2022, then sank by 134.43% to -$198000.0 in 2023, then jumped by 84.85% to -$30000.0 in 2024.
- Per Business Quant, the three latest PVLA Depreciation & Amortization (CF) figures stand at -$30000.0 (Q1 2024), -$198000.0 (Q4 2023), and $739000.0 (Q3 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -30,000.00 |
| Mar 31, 2024 | -30,000.00 |
| Dec 31, 2023 | -198,000.00 |
| Dec 31, 2023 | -198,000.00 |
| Sep 30, 2023 | 739,000.00 |
| Sep 30, 2023 | 739,000.00 |
| Jun 30, 2023 | 758,000.00 |
| Jun 30, 2023 | 758,000.00 |
| Mar 31, 2023 | 605,000.00 |
| Mar 31, 2023 | 605,000.00 |
| Dec 31, 2022 | 575,000.00 |
| Dec 31, 2022 | 575,000.00 |
| Sep 30, 2022 | 767,000.00 |
| Sep 30, 2022 | 767,000.00 |
| Jun 30, 2022 | 583,000.00 |
| Jun 30, 2022 | 583,000.00 |
| Mar 31, 2022 | 845,000.00 |
| Mar 31, 2022 | 845,000.00 |
| Dec 31, 2021 | 609,000.00 |
| Dec 31, 2021 | 609,000.00 |
| Sep 30, 2021 | 608,000.00 |
| Sep 30, 2021 | 608,000.00 |
| Jun 30, 2021 | 617,000.00 |
| Jun 30, 2021 | 617,000.00 |
| Mar 31, 2021 | 625,000.00 |
| Mar 31, 2021 | 625,000.00 |
| Dec 31, 2020 | 688,000.00 |
| Dec 31, 2020 | 688,000.00 |
| Sep 30, 2020 | 754,000.00 |
| Sep 30, 2020 | 754,000.00 |
| Jun 30, 2020 | 530,000.00 |
| Jun 30, 2020 | 530,000.00 |
| Mar 31, 2020 | 339,000.00 |
| Mar 31, 2020 | 339,000.00 |
| Dec 31, 2019 | 265,000.00 |
| Dec 31, 2019 | 265,000.00 |
| Sep 30, 2019 | 159,000.00 |
| Sep 30, 2019 | 159,000.00 |
| Jun 30, 2019 | 42,000.00 |
| Jun 30, 2019 | 42,000.00 |
| Mar 31, 2019 | 166,000.00 |
| Mar 31, 2019 | 166,000.00 |
| Dec 31, 2018 | 195,000.00 |
| Dec 31, 2018 | 195,000.00 |
| Sep 30, 2018 | 130,000.00 |
| Sep 30, 2018 | 130,000.00 |
| Jun 30, 2018 | 141,000.00 |
| Jun 30, 2018 | 141,000.00 |
| Mar 31, 2018 | 134,000.00 |
| Mar 31, 2018 | 134,000.00 |
| Dec 31, 2017 | 101,000.00 |
| Dec 31, 2017 | 101,000.00 |
| Sep 30, 2017 | 55,000.00 |
| Sep 30, 2017 | 55,000.00 |
| Jun 30, 2017 | 113,000.00 |
| Jun 30, 2017 | 113,000.00 |
| Mar 31, 2017 | 100,000.00 |
| Mar 31, 2017 | 100,000.00 |
| Dec 31, 2016 | 224,613.00 |
| Dec 31, 2016 | 224,613.00 |
| Sep 30, 2016 | 92,630.00 |
| Sep 30, 2016 | 92,630.00 |
| Jun 30, 2016 | -11,764.00 |
| Jun 30, 2016 | -11,764.00 |
| Mar 31, 2016 | 94,521.00 |
| Mar 31, 2016 | 94,521.00 |
| Dec 31, 2015 | 73,840.00 |
| Dec 31, 2015 | 73,840.00 |
| Sep 30, 2015 | 79,511.00 |
| Sep 30, 2015 | 79,511.00 |
| Jun 30, 2015 | 76,438.00 |
| Jun 30, 2015 | 76,438.00 |
| Mar 31, 2015 | 78,117.00 |
| Mar 31, 2015 | 78,117.00 |
| Sep 30, 2014 | 278,852.00 |
| Sep 30, 2014 | 278,852.00 |
| Jun 30, 2014 | 189,463.00 |
| Jun 30, 2014 | 189,463.00 |
| Mar 31, 2014 | 95,549.00 |
| Mar 31, 2014 | 95,549.00 |